The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Wahlstrom Mats since 2015.
This trader's CIK number is 1459154.
At the time of last reporting, Wahlstrom Mats was the Director of Trisalus Life Sciences, Inc.. (stock ticker symbol TLSI).
Also see all insider trading activities at Trisalus Life Sciences, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | CHRS | 0 | $0 | 99,988 | $73,891 | 0 | $0 |
| 2024 | CHRS | 0 | $0 | 0 | $0 | 59,988 | $99,999 |
| 2020 | CHRS | 0 | $0 | 318,066 | $5,849,407 | 0 | $0 |
| 2016 | CHRS | 0 | $0 | 53,583 | $1,474,662 | 0 | $0 |
| 2015 | CHRS | 0 | $0 | 130,955 | $4,476,071 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | TLSI | 60,000 | $151,800 | 0 | $0 | 0 | $0 |
| 2024 | TLSI | 15,727 | $69,806 | 0 | $0 | 0 | $0 |
1. Coherus Biosciences, Inc. (CHRS)
2. Trisalus Life Sciences, Inc. (TLSI)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-23 | CHRS | Sale | 99,988 | .74 | 73,891 |
| 2024-02-01 | CHRS | Option Ex | 59,988 | 1.67 | 99,999 |
| 2020-06-17 | CHRS | Sale | 200,000 | 17.15 | 3,429,999 |
| 2020-03-03 | CHRS | Sale | 118,066 | 20.49 | 2,419,408 |
| 2016-12-07 | CHRS | Sale | 7,393 | 27.50 | 203,329 |
| 2016-12-08 | CHRS | Sale | 46,190 | 27.52 | 1,271,333 |
| 2015-08-18 | CHRS | Sale | 6,373 | 33.50 | 213,508 |
| 2015-08-17 | CHRS | Sale | 8,028 | 33.91 | 272,221 |
| 2015-08-14 | CHRS | Sale | 116,554 | 34.24 | 3,990,342 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-05-15 | TLSI | Buy | 60,000 | 2.53 | 151,800 |
| 2024-11-22 | TLSI | Buy | 5,000 | 4.55 | 22,750 |
| 2024-11-20 | TLSI | Buy | 2,040 | 4.16 | 8,486 |
| 2024-11-21 | TLSI | Buy | 8,687 | 4.44 | 38,570 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Wahlstrom Mats (Director of Trisalus Life Sciences, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.